Profile: Cerylid Biosciences Ltd. supplies an extensive library of natural product samples for drug discovery, that include approximately 27,500 microbial cultures and 35,000 plant tissue specimens. Our Cbl1309 is a lead antithrombotic compound with a novel mechanism of action, which specifically targets pathological thrombus formation under conditions of rapid blood flow/high shear stress. We also offer a library of synthetic small molecule PI3K inhibitors with varying profiles of selectivity among the class I PI3K isoforms. In addition to potent & selective PI3Kß inhibitors, the library also contains several potent PI3Kd inhibitors as potential anti-inflammatory lead compounds.